Clinical Trial Update: Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

An update on a Phase 3 trial of a FFP+HDMP+Rituximab regimen for ultra-high-risk chronic lymphocytic leukemia; current status details are not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)
• SOLU-MEDROL (Methylprednisolone sodium succinate)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: UNKNOWN